Compare CHCO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHCO | DNTH |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | CHCO | DNTH |
|---|---|---|
| Price | $119.53 | $39.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $128.33 | $68.00 |
| AVG Volume (30 Days) | 103.9K | ★ 646.6K |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 11.27 | N/A |
| EPS | ★ 8.68 | N/A |
| Revenue | ★ $307,880,000.00 | $3,078,000.00 |
| Revenue This Year | $10.45 | N/A |
| Revenue Next Year | $3.18 | N/A |
| P/E Ratio | $13.74 | ★ N/A |
| Revenue Growth | ★ 6.33 | N/A |
| 52 Week Low | $102.22 | $13.37 |
| 52 Week High | $133.59 | $45.46 |
| Indicator | CHCO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 41.78 |
| Support Level | $118.43 | $40.79 |
| Resistance Level | $124.43 | $43.40 |
| Average True Range (ATR) | 2.49 | 1.73 |
| MACD | -0.70 | -0.47 |
| Stochastic Oscillator | 13.79 | 16.53 |
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.